Rainbow Childrens Medicare Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Rainbow Children's Medicare runs a disclosed, cash-generative hospital business with a clean audit trail and no debt. Three things colour the picture: goodwill from two recent acquisitions sits untested against a history that includes a past impairment and a loss-making subsidiary, a deferred tax credit from that same subsidiary flatters the latest profit growth, and a single customer dominates receivables while pharmacy revenue stays hidden.

Key findings

  1. Goodwill and subsidiary investments grow through acquisitions, yet impairment tests return nil Major - The Group acquired two hospitals for ₹203.6 crore in FY2025-26, with purchase price allocations involving significant judgments and external specialists. The standalone investment in Rosewalk Healthcare, a loss-making subsidiary, was carried at ₹32.41 crore and its impairment assessment was a Key Audit Matter, an area needing the most auditor judgement. Despite recognising a ₹4.63 crore impairment on a subsidiary investment in FY2022-23, the Company reported nil impairment in each of the three subsequent years.
  2. Contingent liabilities are dominated by unresolved land-use and tax disputes, with patient-claim provisions unquantified Minor - The company has not recognised any provision for contingent liabilities from disputes, lawsuits, and patient claims, as management believes none will have a material effect based on external legal advice. A provision for claims other than taxes has been made on a prudent basis for matters pending before courts, but the amount is not disclosed. The Visakhapatnam land allotted in 2010 faced a cancellation order in 2015 and a show-cause notice in 2018, with capital costs of ₹38.4 crore incurred as at 31 March 2023.
  3. A deferred tax credit from a loss-making subsidiary flatters reported PAT growth Minor - In Q4 FY26, PAT growth of 38% was reported, but management stated that excluding a deferred tax adjustment the growth was approximately 17%. The Q4 FY26 investor presentation disclosed that PAT of 78.2 crore included a deferred tax credit of ₹12.95 crore related to wholly owned subsidiary Rosewalk Hospital. As of 31 March 2025, the Group did not recognise deferred tax assets for Rosewalk on unabsorbed depreciation of ₹13.79 crore and brought-forward losses of ₹26.55 crore because it was not probable future taxable profit would be available.
  4. Promoter-executive directors draw rising remuneration requiring special shareholder approval for potential regulatory-limit breaches Minor - Dr. Ramesh Kancharla's total remuneration rose from ₹4.80 crore in FY2022 to ₹6.81 crore in FY2024, then declined to ₹3.13 crore in FY2025 and ₹3.61 crore in FY2026. The company sought special resolutions for promoter-executive director remuneration in FY2024, FY2025, and FY2026 because total managerial remuneration may exceed 11% of net profits under the Companies Act and individual remuneration may exceed ₹5 crore or 2.5% of net profits under SEBI Listing Regulations. The postal ballot resolution to appoint Dr. Adarsh Kancharla, son of the CMD, as Non-Executive Director recorded 15.39% votes against from public shareholders, with public institutions voting 41.86% against.
  5. Trade receivables are concentrated with a single customer that consistently represents 30-42% of total receivables, while pharmacy revenue disclosure is withheld Minor - One customer comprised 30% of consolidated trade receivables as at 31 March 2026, down from 39% a year earlier and 42% at 31 March 2024. No single customer accounted for 10% or more of total revenue in any of the last three years. Management stated in the Q4 FY26 call that "as a matter of policy, we do not disclose pharmacy revenue separately" and directed analysts to estimate it from pharmacy-related costs of "around 12%-13% of revenue".
  6. The company rotated its statutory auditor from BSR & Associates to S.R. Batliboi & Associates after a five-year term, with no resignations or adverse actions reported Clean - BSR & Associates LLP retired at the conclusion of the 25th AGM after being re-appointed at the 20th AGM on 19 July 2018. S.R. Batliboi & Associates LLP was appointed for a five-year term from the 25th AGM, with the shareholder resolution receiving 97.55% votes in favour on 29 June 2023. No resignation of statutory auditors occurred during any year from FY2022-23 through FY2025-26, as confirmed in each year's CARO report.
  7. The group expanded from six to eight subsidiaries in FY26 through two hospital acquisitions, while maintaining a simple structure with no associates, joint ventures, or material subsidiaries Clean - The consolidated group comprised the holding company and six subsidiaries as of FY25, rising to eight subsidiaries as of FY26. Prashanthi Medicare became a subsidiary effective 1 July 2025 and Pratiksha Women & Child Care Hospital became a subsidiary effective 18 August 2025. The company had no associates or joint ventures as of 31 March 2022, and this remained true as of 31 March 2026.

What to watch

Bottom line: This is a disclosed, debt-free hospital platform with cash conversion that covers profit one-and-a-half times over and an auditor rotation executed cleanly. The character of the risk is judgement, not fraud: goodwill from two acquisitions sits on the balance sheet untested by impairment charges, a deferred tax credit from a subsidiary whose own deferred tax assets were not recognised lifts the latest profit number, and a single customer ties up two-fifths of receivables while pharmacy revenue stays off the table. Watch the impairment test, the GST appeal, and the two land disputes.